INS and diabetes mellitus: In a similar way, semaglutide, a glucagon-like peptide (GLP) 1 receptor agonist, a type of diabetes drug, has also been reported to be effective in improving the clinical appearance and severity of NAFLD, such as hepatic steatosis index and AST to platelet ratio index for DM-MAFLD, in addition to improving glycemic control including homeostatic model assessment for insulin resistance index, fat mass, and visceral adipose tissue [18].